[
  {
    "ts": null,
    "headline": "Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.",
    "summary": "Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.",
    "url": "https://finnhub.io/api/news?id=26354dcb8f4b2fac52fa19098477f5d094f89e5c3d2d6cbed96fbbad23b50028",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738251600,
      "headline": "Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.",
      "id": 132500865,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.",
      "url": "https://finnhub.io/api/news?id=26354dcb8f4b2fac52fa19098477f5d094f89e5c3d2d6cbed96fbbad23b50028"
    }
  },
  {
    "ts": null,
    "headline": "Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial",
    "summary": "The trial saw healthy volunteers infected with RSV to test the effectiveness of Shionogi’s treatment.",
    "url": "https://finnhub.io/api/news?id=4a63eac6b40b55c48ed9cc01df7d69c2a72adceb3ad9a78ef9b4743d84603290",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738242211,
      "headline": "Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial",
      "id": 132515253,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/01/New-Project-39.jpg",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The trial saw healthy volunteers infected with RSV to test the effectiveness of Shionogi’s treatment.",
      "url": "https://finnhub.io/api/news?id=4a63eac6b40b55c48ed9cc01df7d69c2a72adceb3ad9a78ef9b4743d84603290"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna (MRNA) Crashed on Wednesday?",
    "summary": "We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday, with all major indices finishing in the red, driven by losses in technology stocks. The Nasdaq […]",
    "url": "https://finnhub.io/api/news?id=6de09ebbddef1cec425f9d0ab89c0c690619af721f44c445f4c4f4527d73dc63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738238092,
      "headline": "Why Moderna (MRNA) Crashed on Wednesday?",
      "id": 132574544,
      "image": "https://s.yimg.com/ny/api/res/1.2/ss7LBw0NkRteO60GW_xAKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3355ab936103e2e5a7e230b963727612",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday, with all major indices finishing in the red, driven by losses in technology stocks. The Nasdaq […]",
      "url": "https://finnhub.io/api/news?id=6de09ebbddef1cec425f9d0ab89c0c690619af721f44c445f4c4f4527d73dc63"
    }
  },
  {
    "ts": null,
    "headline": "Leveragen and Moonlight Bio unite for T-cell therapy development",
    "summary": "The partnership integrates Leveragen’s Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio.",
    "url": "https://finnhub.io/api/news?id=4428c1d273173f134d961460825d2d956eba9cfcca3183d026d59955579fef52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738236991,
      "headline": "Leveragen and Moonlight Bio unite for T-cell therapy development",
      "id": 132574545,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/01/Pharma-2-Levergen-shutterstock_2077684060.jpg",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The partnership integrates Leveragen’s Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio.",
      "url": "https://finnhub.io/api/news?id=4428c1d273173f134d961460825d2d956eba9cfcca3183d026d59955579fef52"
    }
  }
]